The methods of treatment of atrial fibrillation in patients with valvular heart disease

O.M. Grytsay, Y.V. Skybchyk, I.Y. Mokryk, E.V. Zhytyns’kiy, V.О. Kuts, О.J. Zharinov, B.M. Todurov

References  

1. Barnett AS, Kim S, Fonarow GC. et al. Treatment of Atrial Fibrillation and Concordance With the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines: Findings From ORBIT-AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation). Circ Arrhythm Electrophysiol. 2017;10(11):e00505    doi: 10.1161/CIRCEP.117.005051.
2. Barnett SD, Ad N. Surgical ablation as treatment for the elimination of atrial fibrillation: a meta-analysis. J Thorac Cardiovasc Surg. 2006;131(5):1029-1035. doi: 10.1016/j.jtcvs.2005.10.020.
3. Calkins H, Kuck KH, Cappato R. et al. HRS/EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. J Interv Card Electrophysiol. 2012;33(2):171-257. doi:10.1007/s10840-012-9672-7
4. Compier MG, Braun J, Tjon A. et al. Outcome of stand-alone thoracoscopic epicardial left atrial posterior box isolation with bipolar radiofrequency energy for longstanding persistent atrial fibrillation. Neth Heart J. 2016;24(2):143-151. doi: 10.1007/s12471-015-0785-3.
5. Cox J. Current status of the Maze-procedure for the treatment of atrial fibrillation. Seminars Thorac Cardiovasc Surg. 2000;12. Р. 15-19. doi: 10.1016/S1043-0679(00)70011-6.
6. Cox JL. The surgical treatment of atrial fibrillation. IV. Surgical technique. J Thorac Cardiovasc Surg. 1991;101(4):584-592. doi: 10.1016/j.hrthm.2009.05.019.
7. Cox JL, Boineau JP, Schuessler RB. et al. Modification of the Maze-procedure for atrial flutter and atrial fibrillation. I. Rationale and surgical results. J Thorac Cardiovasc Surg. 1995;110:473-484. doi: 10.1016/S0022-5223(95)70244-X.
8. Demaria RG, Page P, Leung TK. et al. Surgical radiofrequency ablation induces coronary endothelial dysfunction in porcine coronary arteries. Eur J Cardiothorac Surg. 2003;23:277-282.  doi: 10.1016/s1010-7940(02)00810-2.
9. Deneke T, Müller P, Halbfaß P. et al. Effect of Different Ablation Settings on Acute Complications Using the Novel Irrigated Multipolar Radiofrequency Ablation Catheter (nMARQ). J. Cardiovasc Electrophysiol. 2015;26(10):1063-1068. doi:  10.1111/jce.12736.
10. Golovchiner G, Mazur A, Kogan A. et al. Atrial flutter after surgical radiofrequency ablation of the left atrium for atrial fibrillation. Ann Thorac Surg. 2005;79(1):108-112. doi:  10.1016/j.athoracsur.2004.06.063.
11. Guiraudon GM, Jones DL, Skanes A. et al. Revisiting right atrial isolation rationale for atrial fibrillation: functional anatomy of interatrial connections. J Interv Card Electrophysiol. 2013;37(3):267-273. doi: 10.1007/s10840-013-9804-8.
12. Huo Y, Christoph M, Forkmann M. et al. Reduction of radiation exposure during atrial fibrillation ablation using a novel fluoroscopy image integrated 3-dimensional electroanatomic mapping system: A prospective, randomized, single-blind, and controlled study. Heart Rhythm. 2015;12(9):1945-1955. doi: 10.1016/j.hrthm.2015.05.018.
13. Ishii Y, Sakamoto SI, Miyagi Y. et al. Risk factors of recurrence of atrial fibrillation (AF) after AF surgery in patients with af and mitral valve disease. Semin. Thorac. Cardiovasc. Surg. 2018;18:44-52. doi: 10.1053/j.semtcvs.2018.01.004.
14. Je HG, Shuman DJ, Ad N. Systematic review of minimally invasive surgical treatment for atrial fibrillation: a comparison of the Cox-Maze procedure, beating-heart epicardial ablation, and the hybrid procedure on safety and efficacy. Eur J Cardiothorac Surg. 2015;48(4):531-540. doi: 10.1093/ejcts/ezu536.
15. Kim JB, Moon JS, Yun SC. et al. Long-term outcomes of mechanical valve replacement in patients with atrial fibrillation: impact of the Maze procedure. Circulation. 2012;125(17):2071-2080. doi: 10.1161/CIRCULATIONAHA.111.082347.
16. Kim JS, Lee JH, Chang HW. et al. Surgical Outcomes of Cox-Maze IV procedure using bipolar irrigated radiofrequency ablation and cryothermy in valvular heart disease. Thorac Cardiovasc Surg. 2011;44(1):18-24. doi:10.5090/kjtcs.2011.44.1.18.
17. Kobza R, Hindricks G, Tanner H. et al. Late recurrent arrhythmias after ablation of atrial fibrillation: incidence, mechanisms, and treatment. Heart Rhythm. 2004;1(6):676-683. doi: 10.1016/j.hrthm.2004.08.009.
18. Lee R, McCarthy PM, Wang EC. et al. Midterm survival in patients treated for atrial fibrillation: a propensity-matched comparison to patients without a history of atrial fibrillation. J. Thorac Cardiovasc Surg. 2012;143(6):1341-1351. doi:10.1016/j.jtcvs.2012.02.006.
19. Liu X, Tan HW, Wang XH. et al. Efficacy of catheter ablation and surgical CryoMaze procedure in patients with long- lasting persistent atrial fibrillation and rheumatic heart disease: a randomized trial. Eur Heart J. 2010;31(21):2633-2641. doi: 10.1093/eurheartj/ehq201.
20. Ma W, Shi W, Wu W. et al. Elevated gradient after mitral valve repair: The effect of surgical technique and relevance of postoperative atrial fibrillation. Thorac Cardiovasc Surg. 2018;27:0022-52. doi: 10.1016/j.jtcvs.2018.07.107.
21. Maltais S, Forcillo J, Bouchard D. et al. Long-term results following concomitant radiofrequency modified maze ablation for atrial fibrillation. J Card Surg. 2010;25:608-613. doi: 10.1111/j.1540-8191.2010.01087.x.
22. Manasse E, Colombo PG, Barbone A. et al. Clinical histopathology and ultrastructural analysis of myocardium following microwave energy ablation. Eur J Cardiothorac Surg. 2003;23(4):573-577.  doi: 10.1016/S1010-7940(02)00835-7.
23. Negi PC, Mahajan K, Rana V. et al. Clinical Characteristics, Complications, and Treatment Practices in Patients With RHD: 6-Year Results From HP-RHD Registry. Glob Heart. 2018;18:89-99. doi: 10.1016/j.gheart.2018.06.001.
24. Paulus K, Stefano B, Dipak K. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210.
25. Pojar M, Haman L, Parizek P. et al. Midterm outcomes of mini-invasive surgical and hybrid ablation of atrial fibrillation. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2018;13:50. doi: 10.5507/bp.2018.050.
26. Sardu C, Marfella R, Testa G. et al. ELectrophysiological mechanisms underlying the Inhibitory CArdiac syncope without asystolic significant pause: Therapeutic and prognostic implications. The ELICA randomized trial. Medicine (Baltimore). 2018;97(31):e11757. doi: 10.1097/MD.0000000000011757.
27. Scheinman MM. Atrial fibrillation therapy: rate versus rhythm control. Pacing Clin Electrophysiol. 2003;26(5):1175-1177. PMID: 12765444.
28. Stewart S, Hart CL, Hole DJ, McMurray JJ. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew. Paisley study. Heart. 2001;86:516-521. doi: 10.1136/heart.86.5.516.
29. Suwalski P, Kowalewski M, Jasiński M. et al.; KROK Investigators. Survival after surgical ablation for atrial fibrillation in mitral valve surgery: Analysis from the Polish National Registry of Cardiac Surgery Procedures (KROK). J Thorac Cardiovasc Surg. 2018;18:32321-3. doi:10.1016/j.jtcvs.2018.07.099.
30. Wazni OM, Chung MK. Catheter ablation for rate-controlled atrial fibrillation: new horizon in heart failure treatment. J Am Coll Cardiol. 2017;70(16):1962-1963. doi:10.1016/j.jacc.2017.08.040.    

Analysis of the drug treatment in patients with stable coronary artery disease before and after surgical myocardial revascularization

О.J. Zharinov, О.А. Yepanchintseva, К.O. Mikhaliev, I.V. Shklianka

References  

1. ESC/EAS Guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2016;37:2999-3058. doi: 10.1093/eurheartj/ehr158.
2. Hillis LD, Smith PK, Anderson JL, Bittl JA. et al. 2011 ACCF/AHA guideline for coronary artery bypass graft surgery: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Thorac Cardiovasc Surg. 2012;143:4-34. doi: 10.1016/j.jtcvs.2011.10.015.
3. Huffmann MD, Xavier D, Perel P. Uses of polypills for cardiovascular disease and evidence to date. Lancet. 2017;389:1055-1065. doi: 10.1016/S0140-6736(17)30553-6.
4. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant. 2013;48(3):452-458.
5. Kulik A, Ruel M, Jneid H. Secondary prevention after coronary artery bypass graft surgery. A Scientific Statement from the American Heart Association. Circulation. 2015;10:927-964.
6. McKavanagh P, Yanagawa B, Zawadowski G, Cheema A. Management and prevention of saphenous vein graft failure: a review. Cardiology and Therapy. 2017;6(2):203-223. doi: 10.1007/s40119-017-0094-6.
7. Montalescot G, Sechtem U, Achenbach S. et al. 2013 ESC guidelines on the management of stable coronary artery disease. The task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J. 2013;34:2949-3003.
8. Neumann F-J, Sousa-Uva M, Ahlsson A. et al. 2018 ESC/EACTS Guidelines on myocardial revascularization The Task Force on myocardial revascularization of the European Society of Cardiology (ESC) and European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association for Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2018;00:1-96. doi: 10.1093/eurheartj/ehy394.
9. Philip F, Blackstone E, Kapadia SR. Impact of statins and beta-blocker therapy on mortality after coronary artery bypass graft surgery. Cardiovasc Diagn Ther. 2015;5(1):8-16.
10. Pinho-Gomes AC, Azevedo L, Ahn JM. et al. Compliance with guideline-directed medical therapy in contemporary coronary revascularization trials. J Am Coll Cardiol. 2018;71:591-602. doi: 10.1016/j.jacc.2017.11.068.
11. Sousa-Uva M, Storey R, Huber K. et al, on behalf of ESC Working Group on Cardiovascular Surgery and ESC Working Group on Thrombosis. Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery. Eur Heart J. 2014;35:1510-1514.
12. Valgimigli M, Bueno H, Byrne RA. et al. The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur Heart J. 2018;39(3):213-260. doi: 10.1093/eurheartj/ehx419.
13. Windecker S, Kolh P, Alfonso F. et al. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg. 2014;46(4):517-592. doi: 10.1093/eurheartj/ehu278.   

Comorbidity and risk of cardiac events in patients with acute coronary syndrome

R.R. Komorovsky

References  

1. Komorovsky RR. Prognostication of the effectiveness of statins for secondary prevention of cardiac events in patients with acute coronary syndrome. Ukr. Cardiol. J. 2008;1:27-32.
2. Andersen H.R, Nielsen T.T, Rasmussen K. et al, for the DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. New Engl J. Med. 2003;349(8):733-742. doi: 10.1056/NEJMoa025142
3. Braunwald E, Antman EM, Beasley JW. et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol. 2000;36:970-1062. doi: 10.1016/S0735-1097(00)00889-5.
4. El Miedany Y. Comorbidity index. In: Comorbidity in rheumatic diseases. Ed. Y. El Miedany. Springer International Publishing AG; 2017:323-344. doi: 10.1007/978-3-319-59962-5.
5. Ibanez B, James S, Agewall S. et al. for the ESC Scientific Document Group. 2017 Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. doi: 10.1093/eurheartj/ehx393
6. Komorovsky R, Desideri A, Coscarelli S, Cortigiani L, Celegon L. Impact of carotid arterial narrowing on outcomes of patients with acute coronary syndromes. Am J Cardiol. 2004;93(12):1552-1555. doi: 10.1016/j.amjcard.2004.03.012
7. Komorovsky R, Desideri A, Coscarelli S. et al. The efficacy of statin therapy in patients with acute coronary syndromes and concomitant carotid disease. Clin Cardiol. 2010;33(2):E15-E19. doi: 10.1002/clc.20610.
8. Maeder MT. Comorbidities in patients with acute coronary syndrome: a rare and negligible in trials but common and crucial in the real world. Heart. 2014;100(4):268-270. doi: 10.1136/heartjnl-2013-305104.
9. Palau P, Núñez J, Sanchis J. et al. Differential prognostic effect of revascularization according to a simple comorbidity index in high-risk non-ST-segment elevation acute coronary syndrome. Clin. Cardiol. 2012;35(4):237-243. doi: 10.1002/clc.20996.
10. Radovanovic D, Seifert B, Urban P. et al. on behalf of the AMIS Plus Investigators. Validity of Charlson comorbidity index in patients hospitalised with acute coronary syndrome. Insights from the nationwide AMIS Plus registry 2002-2012. Heart. 2014;100(4):288-294. doi: 10.1136/heartjnl-2013-304588.
11. Roffi M, Patrono C, Collet J–P et al for the ESC Scientific Document Group. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 2016;37(3):267-315. doi: 10.1093/eurheartj/ehv320.
12. Sanchis J, Núñez J, Bodí V. et al. Influence of comorbid conditions on one-year outcomes in non-ST-segment elevation acute coronary syndrome. Mayo Clin Proc. 2011;86(4):291-296. doi: 10.4065/mcp.2010.0702.
13. Sanchis J, Ruiz V, Bonanad C. et al. Prognostic value of geriatric conditions beyond age after acute coronary syndrome. Mayo Clin Proc. 2017;92(6):934-939. doi: 10.1016/j.mayocp.2017.01.018.
14. Schwartz GG, Olsson AG, Ezekowitz MD et al. for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2011;285(13):1711-1718. doi: 10.1001/jama.285.13.1711.
15. Thygesen K, Alpert JS, Jaffe AS. et al, for the ESC Scientific Document Group. Fourth universal definition of myocardial infarction (2018). Eur Heart J. 2018. doi: 10.1093/eurheartj/ehy462.
16. Valgimigli M, Bueno H, Byrne RA. et al, for the ESC Scientific Document Group. 2017 ESC Focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: Task Force for of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-260. doi: 10.1093/eurheartj/ehx419. 

Atrial fibrillation in acute coronary syndrome: clinical and anamnestic features and effects on the course

 V.І. Tseluyko_, F.B. Salem, N.A. Lopina, I.V. Kuznetsov

References  

1. Lang TA, Sesik M. How to describe statistics in medicine. Moskva: Prakticheskaia meditsina, 2011. 480 p.
2. Lapach SN, Chubenko AV, Babich P.N. Statistical methods in medical-biological research using Excel. Кyiv: Morion, 2001. 408 p.
3. Parkhomenko AN, Lutai YM., Danshan N. The Ukrainian register of acute myocardial infarction as a fragment of the European: characteristics of patients, organization of medical care and hospital therapy. UMJ. 2011. № 1 (81):21-24.
4. Rebrova OY. Statistical analysis of medical data. Application of the STATISTICA application package. Moskva: Media Sphere, 2006. 312 p.
5. Acute coronary syndrome with elevation of segment ST. Order of the Ministry of Health of Ukraine #455 (02.07.2014).
6. Acute coronary syndrome without elevation of segment ST. Order of the Ministry of Health of Ukraine, 2015.
7. Chao TF. et al. Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study. Important because it used a large national health database of people with low CHA2DS2-VASc scores and showed that in similar persons there was an increased risk of MI. Heart Rhythm. 2014;11(11):1941-1947.
8. Chugh SS. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014. 129(8):837-847.
9. Benjamin E, Virani S, Callaway C. et al. Heart disease and stroke statistics-2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67-e492.
10. Ibanez B, James S, Agewall S. et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-177. doi: 10.1093/eurheartj/ehx393.
11. January CT. et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1-76.
12. Kea B, Alligood T, Manning V, Raitt M. A Review of the Relationship of Atrial Fibrillation and Acute Coronary Syndrome. Curr Emerg Hosp Med Rep. 2016;4(3):107-118.
13. Marijon E. et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. Circulation. 2013;128 (20):2192-2201.
14. McManus DD, Huang W, Domakonda KV. et al. Trends in atrial fibrillation in patients hospitalized with an acute coronary syndrome. Amer J Med. 2012;125 (11):1076-1084.
15. Mozaffarian D. et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133 (4):e38-e360.
16. Roffi M, Patrono C, Collet J. et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315.
17. Soliman EZ. et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med. 2014;174(1):107-114.
18. Thygesen K, Alpert JS, Jaffe AS. et al. Executive Group on behalf of the Joint European Society of Cardiology (ESC) / American College of Cardiology (ACC) / American Heart Association (AHA) / World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;30;72(18):2231-2264. doi: 10.1016/j.jacc.2018.08.1038.
19. Rene AG, Généreux P, Ezekowitz M. et al. Impact of atrial fibrillation in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention (from the HORIZONS-AMI [Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction] trial). Am J Cardiol. 2014;113 (2):236-242.
20. Athar MK, Bagga S, Nair N. et al. Risk of cardiac arrhythmias and conduction abnormalities in patients with acute myocardial infarction receiving packed red blood cell transfusions. J Crit Care. 2011;26 (4):335-341.
21. Huang SS, Chan WL, Leu HB. et al. Association between CHADS2 score and the preventive effect of statin therapy on new-onset atrial fibrillation in patients with acute myocardial infarction. PLoS One. 2013;8 (8):e74709. 

Anatomy of the coronary arteries in the congenitally corrected transposition of the great arteries

O.V. Stogova, N.M. Rudenko, O.O. Motrechko, D.O. Shypov

References 

1. Anderson RH, Chiu IS, Spicer DE, Hlavacek AJ. Understanding coronary arterial anatomy in the congenitally malformed heart. Cardiol Young. 2012;22(6):647-654.
2. Dabizzi RP, Barletta GA, Caprioli G. et al. Coronary artery anatomy in corrected transposition of the great arteries. J Am Coll Cardiol. 1988;12(2):486-491.
3. Gittenberger-de Groot AC, Sauer U, Oppenheimer-Dekker A, Quaegebeur J. Coronary arterial anatomy in transposition of the great arteries: a morphologic study. Pediatr Cardiol. 1983;4(I):15-24.
4. Graham TP, Bernard YD, Mellen BG. et al. Long-term outcome in congenitally corrected transposition of the great arteries. J Amer Coll Cardiology. 2000;36(1):255-261.
5. Kwak MK, Jeong YJ, Lee G. et al. An unreported type of coronary artery anomaly in congenitally corrected transposition of great arteries. J Korean Soc Radiol. 2016;75(1):62-67.
6. Mawson JB. Congenital heart defects and coronary anatomy. Tex Heart Inst J. 2002;29(4):279-289.
7. McKay R, Anderson RH, Smith A. The coronary arteries in hearts with discordant atrioventricular connections. J Thorac Cardiovasc Surg. 1996;111(5):988-497.
8. Shaher RM, Puddu GC. Coronary arterial anatomy in complete transposition of the great vessels. Am J Cardiol. 1966;17(3):355-361.
9. Sithamparanathan S, Padley SP, Rubens MB. et al. Great vessel and coronary artery anatomy in transposition and other coronary anomalies: a universal descriptive and alphanumerical sequential classification. JACC Cardiovasc Imaging. 2013;6(5):624-630.
10. Uemura H, Ho SY, Anderson RH. et al. Surgical anatomy of the coronary circulation in hearts with discordant atrioventricular connections. Eur J Cardiothorac Surg. 1996;10(3):194-200.
11. Webb CL. Congenitally corrected transposition of the great arteries: clinical features, diagnosis and prognosis. Progress in Pediatric Cardiology. 1999;10:17-30.

The effect of angle between the graft and coronary artery on volumetric flow rate through the anastomosis

S.S. Galych, A.V. Rudenko, E.A. Nastenko, Yu.S. Starodub

References 

1. Akchurin R, Shiryaev A. Microsurgery of the coronary arteries: recommendations. Мoscow: Geotar-Media, 2012. (in Russ.).
2. Baitinger VF. Vascular suture. Tomsk, 2005. (in Russ.).
3. Gudz U, Balcer K. Reconstractive and endovascular surgery of the infrarenal aorta and the arteries of the lower limb. Ivano-Frankivsc, 2004. 224 p. (in Ukr.).
4. Littmann I. Operative surgery. Budapest: Hungarian Academy of Sciences Publishing. AKADEMIAI KIAD6, 1985. (in Russ.).        
5. Barner HB, Farkas EA. Conduits for Korean. J Thorac Cardiovasc Surg. 2012;45:275-228. doi:10.5090/kjtcs.2012.45.5.275.
6. Cohn LH. Cardiac surgery in the adult. 3rd ed. The McGraw-Hill Companies, 2008.
7. Dhanjoo N Ghista, Foad Kabinejadian. Coronary artery bypass grafting hemodynamics and anastomosis design: a biomedical engineering review. BioMedical Engineering Online. 2013;12:129. doi :10.1186/1475-925X-12-129.          
8. Doty DB, Doty JR. Cardiac surgery: operative technique. 2nd ed. Saunders, 2012.
9. Gardner TJ, Spray TL. Operative Cardiac Surgery. 5th ed. CRC Press, 2004.
10. Gaudino M, Taggart DP. Fifty years after Favaloro, coronary artery bypass surgery is still an ART. Cardiovasc Res. 2018;114 (13):e99-e101. doi: 10.1093/cvr/cvy236.
11. Grus T, Grusová G, Lambert L. et al. The influence of the anastomosis angle on the hemodynamics in the distal anastomosis in the infrainguinal bypass: an in vitro study. Physiol Res. 2016;65 (4):591-595.
12. Jackson ZS, Ishibashi H, Gotlieb A, Lowell Langille B. Effects of anastomotic angle on vascular tissue responses at end-to-side arterial grafts. J Vasc Surg. 2001;34:300-307. doi: 10.1067/mva.2001.115815.
13. Keynton RS, Evancho MM, Sims RL. et al. Intimal hyperplasia and wall shear in arterial bypass graft distal anastomoses: an in vivo model study. J Biomech Eng. 2001;123:464-473.
14. Selke F, Ruel M. Atlas of Cardiac Surgical Techniques. 1st ed. Saunders, 2010.
15. Wadey K, Lopes J, Bendeck M, George S. Role of smooth muscle cells in coronary artery bypass grafting failure. Cardiovasc. Res. 2018;114 (4):601-610.   

Clinical course and remodeling of left ventricle in patients with ST segment elevention acute myocardial infarction after primary coronary artery stenting

V.A. Skybchik, Yu.P. Melen

References  

1. Farahani E, Saadat H. The Effect of percutaneous coronary intervention on isolated left ventricular diastolic dysfunction in patients with coronary artery disease assessed by using strain rate imaging. J Cardiol Clin Res. 2014;2(3):1037.
2. Hashemi SR, Motamedi M, Khani M. et al. Evaluation of the effect of elective percutaneous coronary intervention as a treatment method on the left ventricular diastolic dysfunction in patients with coronary artery disease. J. Tehran University Heart Center. 2010;5(4):194-198.
3. Iwanaga Y, Nishi I, Furuichi S. et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. J. Am. Coll. Cardiol. 2006;47:742-748.
4. Lagerqvist B, Husted S, Kontny F. et al. Fast Revascularisation during InStability in Coronary artery disease (FRISC-II) Investigators 5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study. Lancet. 2006;16:998-1004.
5. Naqvi TZ, Padmanabhan S, Rafii F. et al. Comparison of usefulness of left ventricular diastolic versus systolic function as a predictor of outcome following primary percutaneous coronary angioplasty for acute myocardial infarction. Am. J. Cardiol. 2014;97:160-166.
6. Schannwell CM, Schneppenheim M, Plehn G. et al. Parameters of left ventricular diastolic function 48 hours after coronary angioplasty and stent implantation. J. Invasive Cardiol. 2003;15:326-333.
7. Seok-Jae H, Vojtech M, Barry A. et al. Implications of coronary artery disease in heart failure with preserved ejection fraction (Mayo clinic). J. Amer. Coll. Cardiology. 2014;63:2817-2827. doi: 10.1016/j.jacc.2014.03.034.
8. Spertus JA, Winder JA, Dewhurst TA. et al. Development and evaluation of the Seattle Angina Questionnaire: a new functional status measure for coronary artery disease. J. Am. Coll. Cardiol. 1995;25(2):333-341.
9. Sahinarslan A, Cengel A, Okyay K. et al. B-type natriuretic peptide and extent of lesion on coronary angiography in stable coronary artery disease. Cor. Art Dis. 2005;16:225-229.
10. Morita E, Yasue H, Yoshimura M. et al. Increased plasma levels of brain natriuretic peptide concentrations in patients with acute myocardial infarction. Circulation. 1993;88:82-91.
11. Olenchock BA, Wiviott SD, Murphys SA. et al. Lack of association between soluble CD40L and risk in large cohort patient with ACS in OPUS TIMI 16. J. Thromb. Thrombolysis. 2008;26(2):79-84.
12. Seino Y, Ogawa A, Yamashita T. et al. Application of NT-proBNP and BNP measurements in cardiac care: A more discerning marker for the detection and evaluation of heart failure. Eur. J. Heart Failure. 2004;6:295-300.